The proteasome inhibitor bortezomib induces apoptosis in multiple myeloma cells and has transformed patient outcome. Using in vitro as well as in vivo immunodeficient and immunocompetent murine multiple myeloma models, we here show that bortezomib also triggers immunogenic cell death (ICD), characterized by exposure of calreticulin on dying multiple myeloma cells, phagocytosis of tumor cells by dendritic cells, and induction of multiple myeloma–specific immunity. We identify a bortezomib-triggered specific ICD gene signature associated with better outcome in two independent cohorts of patients with multiple myeloma. Importantly, bortezomib stimulates multiple myeloma cell immunogenicity via activation of the cGAS/STING pathway and production of type I IFNs, and STING agonists significantly potentiate bortezomib-induced ICD. Our study therefore delineates mechanisms whereby bortezomib exerts immunotherapeutic activity and provides the framework for clinical trials of STING agonists with bortezomib to induce potent tumor-specific immunity and improve patient outcome in multiple myeloma.

Annamaria Gulla, Eugenio Morelli, Mehmet K Samur, Cirino Botta, Teru Hideshima, Giada Bianchi, et al. (2021). Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. BLOOD CANCER DISCOVERY, bloodcandisc.BCD-21-0047-A.2021 [10.1158/2643-3230.BCD-21-0047].

Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation

Cirino Botta;
2021

Abstract

The proteasome inhibitor bortezomib induces apoptosis in multiple myeloma cells and has transformed patient outcome. Using in vitro as well as in vivo immunodeficient and immunocompetent murine multiple myeloma models, we here show that bortezomib also triggers immunogenic cell death (ICD), characterized by exposure of calreticulin on dying multiple myeloma cells, phagocytosis of tumor cells by dendritic cells, and induction of multiple myeloma–specific immunity. We identify a bortezomib-triggered specific ICD gene signature associated with better outcome in two independent cohorts of patients with multiple myeloma. Importantly, bortezomib stimulates multiple myeloma cell immunogenicity via activation of the cGAS/STING pathway and production of type I IFNs, and STING agonists significantly potentiate bortezomib-induced ICD. Our study therefore delineates mechanisms whereby bortezomib exerts immunotherapeutic activity and provides the framework for clinical trials of STING agonists with bortezomib to induce potent tumor-specific immunity and improve patient outcome in multiple myeloma.
Annamaria Gulla, Eugenio Morelli, Mehmet K Samur, Cirino Botta, Teru Hideshima, Giada Bianchi, et al. (2021). Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. BLOOD CANCER DISCOVERY, bloodcandisc.BCD-21-0047-A.2021 [10.1158/2643-3230.BCD-21-0047].
File in questo prodotto:
File Dimensione Formato  
Bortezomib induces anti-multiple myeloma immune response.pdf

non disponibili

Tipologia: Pre-print
Dimensione 4.88 MB
Formato Adobe PDF
4.88 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/513407
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact